28 July 2026
Guinness Ventures has participated in Qureight’s $20 million Series B financing, led by Molten Ventures alongside existing investors Hargreave Hale AIM VCT, XTX Ventures, Meltwind and Ascension.
Founded in Cambridge, Qureight has developed an end-to-end, AI-powered imaging platform that helps pharmaceutical companies improve the design, execution and analysis of clinical trials.
The funding will support the continued development of Qureight’s quantitative imaging platform, the creation of a dedicated AI imaging laboratory and the company’s expansion into additional therapeutic areas.
About Qureight
Qureight has developed an end-to-end imaging platform designed to help pharmaceutical companies improve the design, execution and analysis of clinical trials.
The company combines enterprise-grade imaging technology with advanced artificial intelligence to generate quantitative imaging biomarkers and clinical insights. These tools can help accelerate the development of new treatments for patients with serious lung and heart diseases.
The opportunity
Better imaging can support better clinical trials
More precise measurement of disease progression can help improve trial design, identify suitable patients more efficiently and provide stronger evidence of whether a treatment is effective.
Qureight’s platform has been developed specifically to provide pharmaceutical companies with the imaging services, analysis and data science tools needed to make faster and more informed clinical decisions.
Addressing one of healthcare’s biggest challenges
Clinical trials remain one of the most expensive and time-consuming stages of drug development. Qureight is seeking to improve this process by making imaging data more measurable, consistent and clinically useful.
Trial design
More precise measurement
Quantitative imaging can help researchers measure changes in disease more accurately and improve how clinical trials are structured.
Patient selection
Better-informed recruitment
Imaging biomarkers can support the identification of patients whose disease characteristics are appropriate for a particular trial.
Clinical evidence
Stronger treatment insights
Consistent analysis of imaging data can help pharmaceutical companies evaluate treatment effectiveness and make more informed development decisions.
Qureight currently supports biopharmaceutical companies developing treatments for fibrotic lung diseases, providing imaging services, AI-powered analysis and specialist data science tools.
Supporting the next phase of growth
The Series B funding will enable Qureight to expand its next-generation, AI-powered quantitative imaging platform and establish a dedicated AI imaging laboratory centred on its 3D chest imaging foundation model.
01
Develop the platform
Continue expanding Qureight’s quantitative imaging and AI analysis capabilities.
02
Build an AI imaging laboratory
Establish a dedicated laboratory centred on Qureight’s 3D chest imaging foundation model.
03
Enter new therapeutic areas
Support expansion into asthma, pulmonary hypertension, bronchiectasis and drug-induced lung toxicity.
The foundation model is intended to reduce the time and data required to develop new disease models, helping Qureight apply its technology across a broader range of conditions.
The investment will also support the continued growth of the company’s commercial team, enabling Qureight to meet increasing demand from pharmaceutical customers and further strengthen its position as a specialist imaging partner for global clinical trials.
Why we invested
Guinness Ventures first invested in Qureight in March 2024, impressed by the strength of the team and the significance of the problem it was seeking to solve.
The business fits well with our investment thesis. We look to back companies addressing significant global challenges through differentiated technology, strong intellectual property and experienced leadership teams.
Qureight brings together clinicians, scientists, engineers and AI specialists to solve a complex problem at the heart of modern drug development.
Its technology is already being deployed in clinical trials, and we believe the business is well positioned to expand across multiple therapeutic areas as demand for AI-enabled clinical development continues to grow.